A phase I dose-escalation study of LAE001/prednisone plus afuresertib in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment

被引：0
|
作者：
Bessudo, A. [1 ]
Wang, X. [2 ]
Strauss, J. F. [3 ]
Slater, D. E. [4 ]
Pieczonka, C. [5 ]
Guo, P.
Liu, J. [6 ]
Yue, Y. [2 ,6 ]
Lu, C. [7 ]
机构：
[1] Scripps Mem Hosp Encinitas, Hematol & Oncol, Encinitas, CA USA
[2] Laekna Therapeut, Clin Dev, Warren, NJ USA
[3] Med City Hosp, Dept Oncol, Dallas, TX USA
[4] Eastern Connecticut Hematol & Oncol Assoc, Hematol Oncol, Norwich, CT USA
[5] Upstate Community Hosp, Dept Urol, Syracuse, NY USA
[6] Laekna Therapeut, Biomet, Shanghai, Peoples R China
[7] Laekna Therapeut, Clin Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1112
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
599P
引用
收藏
页码：S644 / S645
页数：2
相关论文
共 50 条
  • [1] A phase I dose-escalation study of LAE001 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Ye, D.
    Liu, R.
    Luo, H.
    Han, W.
    Lu, X.
    Cao, L.
    Guo, P.
    Liu, J.
    Yue, Y.
    Lu, C.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S643 - S643
  • [2] A phase I/II efficacy and safety study of LAE001/prednisone and afuresertib in patients with metastatic castrationresistant prostate cancer (mCRPC) following 1-3 lines of standard of care
    Diamond, E.
    Kwak, C.
    Orr, D.
    Bamidele, A.
    Jeong, I. G.
    Bessudo, A.
    Dunshee, C.
    Henderson, S.
    Joung, J. Y.
    Lee, S.
    Chaves, J.
    Slater, D.
    Patnaik, A.
    Pieczonka, C.
    Lee, W.
    Choi, Y. D.
    Guo, P.
    Ma, K.
    Cao, E.
    Yue, Y.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S985 - S985
  • [3] A phase I dose escalation study of PCUR-101 in men with metastatic castration-resistant prostate cancer (mCRPC).
    Kyriakopoulos, Christos
    Paller, Channing Judith
    Verma, Ajit
    Kader, Karim
    Kittrelle, Jeff
    Borgstrom, Per G.
    Vaishampayan, Ulka N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana
    Christos, Paul
    Hackett, Amy
    Nordquist, Luke
    Gelmann, Edward
    Stein, Mark
    Sternberg, Cora
    Beltran, Himisha
    Gracey, Lauren
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [5] A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).
    Sun, Michael
    Nauseef, Jones T.
    Lebenthal, Justin M.
    Niaz, Muhammad Junaid
    Singh, Sharon
    Chamberlain, Tessa A.
    Bissassar, Mahelia
    Patel, Amie
    Tan, Angela
    Vallabhajosula, Shankar
    Babich, John
    Christos, Paul J.
    Osborne, Joseph
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [6] Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Vallabhajosula, Shankar
    Jhanwar, Yuliya
    Ballman, Karla V.
    Hackett, Amy
    Emmerich, Lauren
    Babich, John
    Sartor, A. Oliver
    Harshman, Lauren Christine
    Beltran, Himisha
    Molina, Ana M.
    Nanus, David M.
    Bander, Neil Harrison
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [7] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    [J]. UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [8] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Werner, Lillian
    Erlander, Mark G.
    Ridinger, Maya
    Bubley, Glenn
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [9] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [10] A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345